Press Coverages & Releases
by: AZO MATERIALS
3D bioprinting is an emerging technology with applications across the full spectrum of biomedical research. The technique directly builds on 3D printing technologies using a biological substrate or ‘bioink’, comprised of cells, structural components and growth media, to create 3D biological structures that closely mimic the arrangement of cells in living organisms.
Using the same additive manufacturing model as conventional 3D printing, a computer breaks down a 3D model into a number of 2D slices to print a precise biological structure layer-by-layer with a specific arrangement of cells and tissues.
3D bioprinting presents an opportunity to overcome challenges in regenerative medicine, drug development, cancer treatment and organ donation. As with any emerging technology, researchers are also developing solutions to its own challenges to maximize the potential of this game-changing tool.
by: AZO MATERIALS
SunP Biotech is a new company that focuses its efforts on the 3D bio-manufacturing sector. We design and manufacture bioprinters which are used for advanced biomedical research. We also develop and manufacture bio-inks that can be used with any bioprinters to build tissue-specific structures very easily.
The advantage of 3D printing, as it is a subset of additive manufacturing, is the ability to use the least amount of necessary material to build whatever you want to make. However, 3D printing is effectively adding material to build the part, only using as much material as the final product requires. It is a less wasteful process.
by: Margaret Harris, Biofabrication, IOP Publishing
Creating whole organs in the lab is a distant dream. Some experts think it always will be. But as innovations in 3D bioprinting begin to filter out of research groups and into the commercial and clinical worlds, less headline-grabbing advances could nevertheless prove significant, as Margaret Harris reports
In biomedical science there are dreams and there are realities. Here is one of the realities: right now, more than 5000 people in the UK need a new kidney. Over the next year, after a median wait of about 30 months, slightly fewer than half of them will receive one. The rest will continue to wait, but they cannot hold on forever: in 2016, 457 Britons died while waiting for a new kidney, liver, heart or lung. Another 875 were taken off the waiting list, mostly because they had become too ill to receive a transplant.
REPORT: Global 3D Bioprinting Technologies, Products and Key Application Areas 2017-2018 & Forecasts to 2035
by: Research and Markets, Laura Wood, Senior Manager
The 3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035′ report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. The field has seen the emergence of many new players in the past few years; in fact, several well-known players of the 3D printing industry have broadened their focus to launch new initiatives specific to 3D bioprinting.
3D printing has garnered significant attention within the healthcare industry. The concept of 3D bioprinting was conceived in the late 1990s; since then, various industry stakeholders and academicians have undertaken several initiatives in order to further develop / improve this technology for a variety of applications. Organovo was the first company to enter the 3D bioprinting space by printing functional blood vessels in 2010. The company now offers 3D printed kidney and liver tissue models. There have been a number of other notable attempts to create fully functional 3D bioprinted tissues.
The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. Owing to the evident interspecies differences, drug candidates that are shown to be efficacious in animal models often fail in humans. For such purposes, 3D bioprinting can be used to develop more accurate, human specific disease models. Further, there is a severe unmet need when it comes to organ transplants. Therefore, the ability to synthetically create organs for transplantation purposes is expected to generate a lot of interest amongst pharmaceutical / biotechnology players in the coming years.
The current market landscape of 3D bioprinting is characterized by the presence of nearly equal number of industry and non-industry players, featuring a number of startups and university spin-offs. Although there are several 3D bioprinting technologies already available, active efforts are being made to add to the intellectual property portfolio. The field has witnessed growing partnering activity and has also managed to capture the interest of both public and private sector investors.Despite certain challenges, several technical advancements and high unmet need of current patients waiting for organ transplants is anticipated to significantly drive future growth.